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Drug courts began in 1989 in Miami-Dade County, Florida, U.S.A.  Due to their success in 
treating substance use disorders and reducing criminal recidivism, they have expanded globally 
and are currently operating in countries such as Australia, Canada, and Scotland, to name a few.  
Drug courts can be a key intervention in addressing the opioid epidemic.  This is the first known 
qualitative study to ask drug court participants (n = 38) who have an opioid use disorder 
questions related to their lived experiences in drug court, as well as direct questions related to the 
use of medication assisted treatments (MATs) in drug court.  Overall, drug court participants felt 
that MATs were helpful for treating their opioid use disorders; however, some participants 
reported using other drugs while on MATs and they viewed their recovery through a harm 
reduction lens.  Additionally, participants emphasized the importance of using MATs in 
combination with counseling that used cognitive and behavioral therapies.  Implications for drug 
court practice and future research are discussed.   
 












 The United States of America (U.S.) is currently experiencing an opioid epidemic that is 
having devastating consequences on individuals and families, the healthcare system, criminal 
justice system, and overall economic wellbeing of the country.  In 2015, more than 33,000 
Americans died prematurely from an opioid-related drug overdose (The Council of Economic 
Advisers, 2017).  Overall, the estimated economic impact of the opioid epidemic on the U.S. is 
$504 billion dollars; this estimate includes all consequences of the opioid epidemic, including 
overdose deaths and other expenses such as increased criminal justice costs for the policing, 
arresting, and incarceration of individuals who possess or sell illicit opioids (The Council of 
Economic Advisors, 2017).   
 While the negative consequences of the opioid epidemic seemed to have appeared 
rapidly, the epidemic is actually an unintended consequence of U.S. medical trends that began 
approximately three decades ago (U.S. Department of Health and Human Services [HHS], 2018).  
During the 1990s, prescriptions for opioids began to increase and become one of the standard, 
first options for treating pain.  Recent data show that U.S. pharmacies dispensed 214,881,622 
opioid prescriptions in 2016, resulting in 66.5% of Americans receiving a prescription opioid 
that year (Center for Disease Control and Prevention, 2017).  In 2017, opioid addiction was 
declared a national public health emergency (HHS, 2018).    
 As the number of opioid prescriptions has climbed, the rates of opioid use disorders have 
increased, too.  Although not a process that happens for everyone, prescription opioid use can 
progress to illicit drug use via the development of tolerance and withdrawal, two primary 
symptoms of a substance use disorder (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2018).  For instance, an individual who has been taking an opioid 
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(e.g. Vicodin) as prescribed may develop a physiological tolerance to the drug and therefore need 
more of the drug to get the desired effect.  They may take more of their medication than 
prescribed and therefore not have enough to last an entire month, leading to withdrawal when 
they no longer have the medication. To avoid powerful and overwhelming withdrawal 
symptoms, the individual may turn to illicit behavior such as buying heroin or fentanyl illegally.  
This pattern is common, and many illicit opioid users originally began their use with prescription 
opioids (Center for Disease Control and Prevention, 2017).  Thus, if effective treatment is not an 
option, many opioid dependent individuals may resort to criminal behavior to sustain their 
substance dependence.  Besides the resultant increased risk of criminal justice involvement, users 
of illicit opioids are also at higher risk of overdose and death due to the powerful nature of these 
drugs and the difficulty in estimating their strength when buying illegally; U.S. opioid-related 
overdoses are currently at an all-time high (Rudd, Seth, David, & Scholl, 2016). 
The U.S. criminal justice system is overburdened with people who have been convicted 
of drug-related crimes, yet lacks the ability to effectively treat substance use disorders.  Nearly 
half a million Americans were incarcerated for drug-related offenses in 2016 (The Sentencing 
Project, 2018).  At the federal level, nearly half of the prison population is comprised by people 
who had drug-related convictions. However, only about 15% of inmates who have drug use 
disorders receive needed treatment (Bronson, Stroop, Zimmer, & Berzofsky, 2017).  The opioid 
epidemic has contributed to these rates, and approximately 22% of incarcerated individuals 
report regularly using heroin or other opiates prior to their incarceration (Bronson et al., 2017).   
  Medication assisted treatments (MATs) are a harm-reduction approach taken to reduce 
the risk of morbidity, mortality or other negative consequences of chronic opioid misuse.  With 
MATs, opioid agonist medications are prescribed and closely monitored to control the level of 
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medication ingested, thereby reducing drug-seeking behaviors and intense highs and withdrawal 
periods associated with illicit drug use (National Institute on Drug Abuse [NIDA], 2016; 
SAMHSA, 2018; Volkow, 2014).   Prescribed opioid agonists have been found to decrease risk 
of mortality, illicit opioid use, infectious disease transmission, and criminal activity as well as 
increase employment for people who are dependent on opioids (NIDA, 2016).  However, these 
medications are not always used or encouraged by the criminal justice system due to an 
abstinence-based philosophy of drug treatment or concerns about potential drug diversion 
(Friedmann et al., 2012).  
Use of the Criminal Justice System for Treatment 
  The criminal justice system can play a key role in addressing the opioid epidemic, 
particularly by providing enhanced treatment and recovery services to individuals coming in 
contact with the system.  This addresses one of the U.S. Department of Health and Human 
Service’s (HHS) priorities for addressing the opioid epidemic, enhanced treatment and recovery 
services for people with opioid use disorders (HHS, 2017).  Drug courts are one such option for 
ensuring that treatment and recovery-related services are combined with the criminal justice 
system, both in the U.S. and internationally.   
Drug courts are specialized programs that target offenders with substance use disorders or 
drug-related crimes.  These programs are problem-solving courts that provide screening and 
assessment, treatment and recovery services, monitoring, and progressive incentives/sanctions to 
provide support for recovery.  Drug courts have seen tremendous growth both inside and outside 
the U.S. since beginning in 1989, and there are now approximately 3,100 drug courts in the U.S. 
(U.S. Department of Justice, 2018).  Drug courts have expanded globally, operating in countries 
such as Australia, Brazil, Canada, England, Ireland, Jamaica, and Scotland (Holst, 2010).   
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Three decades of evidence have shown that drug courts appear to be more effective than 
traditional criminal justice interventions (such as probation) at reducing criminal recidivism rates 
for individuals who have substance use disorders and arrests for nonviolent offenses.  The 
evidence that drug court participants recidivated at lower rates than comparison and control 
groups is highlighted in quasi-experimental studies of single drug courts (Brown, 2011; 
Gallagher et al., 2015), rigorous evaluations that used experimental research designs 
(Gottfredson & Exum, 2002; Gottfredson, Najaka, & Kearley, 2003) and meta-analytic reviews 
(Mitchell, Wilson, Eggers, & MacKenzie, 2012; Shaffer, 2011a).   More recent studies have 
moved beyond quantitative outcome studies to focus qualitatively and primarily on 
understanding barriers to and improving outcomes for certain populations that drug courts serve, 
such as women or African Americans (see Gallagher & Nordberg, 2017; Gallagher & Wahler, 
2018; Vandermause, Severtsen, & Roll, 2013).  However, no known studies have examined the 
lived experiences of drug court participants who have opioid use disorders. 
Drug Courts and Treatment of Opioid Use Disorders 
Although designed to ensure offenders receive needed drug treatment, U.S. drug courts 
have been criticized for sometimes failing at this goal (Matsuow et al., 2013; Mehta & 
Møllmann, 2017).  A recent survey of drug courts in the U.S. found that nearly all drug courts 
surveyed (98%) served participants who had opioid use disorders, yet only 56% offered or 
allowed MATs (Matsuow et al., 2013).  Observed barriers to using MATs in drug court included 
cost, but also opposition from key stakeholders, such as the drug court judge and prosecutor 
(Matusow et al., 2013).   In a similar study, Friedmann and colleagues (2012) also found that 
MATs were infrequently allowed or used in criminal justice settings, such as drug courts, 
probation, and parole.  When used, MATs were most frequently used by pregnant women who 
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had opioid use disorders and were in opioid withdrawal.  This is most likely because of federal 
and international guidelines urging the use of MATs for opioid-dependent pregnant women due 
to the associated reduction in risk and harm to the fetus (American College of Obstetricians and 
Gynecologists, 2017). Friedmann et al. (2012) found that non-pregnant drug court participants or 
individuals re-entering the community after incarceration were commonly denied or did not have 
access to MATs, despite the benefit these populations could also gain from these treatments.   
The lack of MATs used in some drug courts may contribute to participants who have 
opioid use disorders having poorer outcomes, such as lower graduation rates or higher relapse or 
recidivism rates.  A recent study by Gallagher and colleagues (2018b) found that participants 
who identified opioids as the primary drug used were 80% less likely to graduate, as compared to 
drug court participants who identified non-opioids as their primary drug.  Only 30% of 
participants who primarily used opioids successfully completed drug court, whereas nearly 70% 
of participants successfully completed who primarily used non-opioids.  Therefore, developing 
an in-depth understanding of drug courts and how they serve participants who have opioid use 
disorders is a priority.  The current study is the first known qualitative study to explore the lived 
experience of drug court participants who have an opioid use disorder and their opinions about 
the use of MATs in drug court.   
Methodology 
Qualitative Research Design and Sampling 
 This study was approved by the Institutional Review Board (IRB) at the authors’ 
university.  The population of interest was drug court participants who have an opioid use 
disorder, so all participants were recruited from this group and self-identified as having been 
diagnosed.  Participants were asked the questions in Table 1, focused on their perceptions of 
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helpful aspects of drug court, how drug court could be more helpful, the benefits and challenges 
of using MATs, and whether drug court effectively uses MATs to treat people who have opioid 
use disorders.  These questions were asked in focus groups, which are recommended when 
research participants have similar characteristics, such as being a member of drug court and 
having an opioid use disorder, and due to these similarities, may complement one another’s 
experiences and add to an in-depth understanding of a particular phenomenon (Padgett, 2016; 
Rubin & Babbie, 2008).   
Table 1 Focus Group Questions  
 
1. Could you please describe what aspects of drug court are most helpful to you in treating your  
opioid use disorder? 
 
2. Could you please describe how drug court could be more helpful to you in treating your opioid 
use disorder?  
 
3. Could you please describe your thoughts and/or experiences on the benefits of using 
medication-assisted treatments to treat your opioid use disorder? 
 
4. Could you please describe your thoughts and/or experiences on the challenges of using 
medication-assisted treatments to treat your opioid use disorder?   
 
5. Could you please describe your thoughts and/or experiences on whether or not the drug court 
effectively utilizes medication-assisted treatments to treat participants who have opioid use 
disorders? 
 
Research participants (n = 38) were recruited in 2018 from one drug court located in a 
Midwestern state in the U.S.  Two researchers attended six drug court hearings, which were held 
every Monday, to recruit research participants.  The two researchers facilitated one focus group 
each Monday immediately after the hearing for consenting participants; therefore, they attended 
multiple drug court hearings to assure all who were eligible to participate in the research had an 
opportunity to do so.  During the recruitment process, the researchers introduced themselves, 
described the research question and format of focus groups, highlighted that participation in the 
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research was voluntary and confidential, and mentioned the inclusion criteria.  Inclusion criteria 
were: (1) must be a current participant in the drug court; (2) must be able to comprehend, speak, 
and read English; (3) must be 18 years of age or older; and (4) must have an opioid use disorder.  
Individuals who met the inclusion criteria and volunteered to participate were scheduled for the 
focus group after their hearing.  In order to promote convenience for the research participants, 
the focus groups were facilitated in the same building as the drug court, but on a different floor.  
Focus groups were facilitated in a private, closed conference room on a secure floor. 
The focus groups were co-facilitated by two researchers and audio reordered.  The focus 
groups were semi-structured; specifically, research participants were asked the five open-ended 
questions noted in Table 1 and probing questions were used to develop an in-depth 
understanding of their lived experiences in drug court.  For example, the researchers used 
validating statements and probing questions such as, “It sounds like you benefited from using 
Suboxone (buprenorphine/naloxone).  Could you please elaborate on the specific benefits you 
received by using the medication?” and “Balancing all the responsibilities of drug court with life 
seems to be a challenge.  Could you please further describe the specific challenges you face?”  
Informed consent was received by all those who chose to participate in a focus group.   
Qualitative Data Analysis Plan 
The audio recordings of the focus groups were transcribed verbatim and uploaded to 
NVivo, a qualitative data analysis software.  According to Miles, Huberman, and Saldana (2014), 
qualitative data analysis is theoretically driven; the data from this study were analyzed through a 
phenomenological lens.  Phenomenological analysis explores the lived experiences of research 
participants, as well as the context of those experiences (Padgett, 2016).  In this study, research 
participants were asked questions about their lived experiences in drug court and also 
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encouraged to elaborate on how the experiences have impacted their lives, or perhaps the lives of 
others.  The qualitative data analysis followed a four-step process (Miles et al., 2014; Rubin & 
Babbie, 2008) and strategies, such as negative case analysis, were used to increase the rigor of 
the data analysis and validity of the findings (Padgett, 2016).  First, to promote immersion in the 
data, the researchers read the transcriptions on four occasions over a two-week period.  During 
this time, and consistent with phenomenological analysis, the lived experiences of drug court 
participants were continuously compared and contrasted to develop insight into the research 
question.  Second, concept mapping was used to group data, identify codes, and provide a 
conceptual framework for the findings. Third, codes were grouped as themes, the number of 
research participants who contributed to each theme was quantified, and direct codes from the 
research participants were used to conceptualize each theme.  Fourth, data that did not 
demonstrate consistent responses from the research participants were considered outliers and 
used for the negative case analysis. 
Four strategies were used to increase the rigor of the data analysis and validity of the 
findings (Padgett, 2016).  First, the data collection and analysis were completed by researchers 
from different disciplines (criminal justice, psychology, and social work) offering 
interdisciplinary triangulation.  Second, peer debriefing allowed the researchers to share their 
preliminary codes and themes with colleagues who had expertise in qualitative research and seek 
their feedback on the logic of the data analysis and preliminary findings. Peer debriefing was 
completed via email and phone calls.  Those involved in the peer debriefing process had access 
to all the transcripts, which were in anonymous format, meaning no names or other potential 
identifying information was on the transcripts.  Third and fourth, negative case analyses and 
audit trails were completed for each theme, and the negative cases are presented in the findings 
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section. The negative case analyses promote a balanced interpretation of the findings, and the 
audit trails provide an additional avenue to verify the findings. 
Findings 
Thirty-nine drug court participants met the inclusion criteria and 38 chose to participate, 
providing a response rate of 97%.  From May 2018 to July 2018, the researchers facilitated 6 
focus groups.  A brief demographic survey was given at the start of each focus group.  The 
average age of focus group participants was 34 years old and the majority were male (63% male, 
n = 24; 37% female, n = 14).  Almost three-fourths of the sample were White (71% White, n = 
27; 29% non-White, n = 11).  The focus group questions (Table 1) were related to participants’ 
thoughts and experiences in drug court and the use of MATs to support recovery.  All (100%, n = 
38) of the research participants had an opioid use disorder, and the majority (58%, n = 22) had 
been on a MAT at some point in their life.  Furthermore, 37% (n = 14) of the research 
participants were on a MAT at the time of the focus group.  For the participants who were on a 
MAT at the time of the focus group (n = 14), 50% (n = 7) were on Suboxone 
(buprenorphine/naloxone), 29% (n = 4) on Vivitrol (naltrexone), and 21% (n = 3) on methadone.  
Throughout the analysis, two primary themes emerged from the data, as discussed below. 
The importance of combining MATs with cognitive and behavioral therapies 
Twenty-three of the 38 participants (61%) shared thoughts, opinions, and lived 
experiences about their perceptions of the importance of combining MATs with psychosocial 
treatments such as cognitive and behavioral therapies.  This theme is demonstrated through the 
quotes below.  Overall, the majority of participants shared that one of the most helpful aspects of 
drug court in treating their opioid use disorders was participating in treatment.  One participant, 
for instance, shared that whether or not you are on a MAT, cognitive or behavioral treatment is 
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helpful in many areas of life, such as family relationships and employment.  She also mentioned 
the importance of learning healthy coping skills, which tend to be taught through cognitive and 
behavioral therapies.  Specifically, she said: 
I’m in the women’s matrix program at [name of treatment center] and it’s a lot 
different than IOP [intensive outpatient program].  We talk about different life 
skills, how to cope with drugs, family life, work life, everything. Whether you are 
on a medication-assisted treatment or not, for us with heroin addictions, it’s 
important for us to attend treatment each week.    
Another participant discussed how opioid use negatively impacted his cognitions.  The 
participant also noted the importance of combining MATs with other forms of treatment, 
specifically cognitive restructuring in his case.  The participants shared: 
It’s good to get into treatment right away.  It gives you at least a head start, you 
know?  Trying to go through all of this with being sick and being out there on the 
streets is impossible.  We need Suboxone or whatever else helps and treatment.  
Like I said, it gives you a head start. The counselors teach you how to think clear 
because when you’re using drugs, you aren’t thinking straight.  Your mind 
changes completely, you know, and it gets your mind thinking, I can start life 
again.    
The following participant shared a lived experience highlighting the importance of combining 
MATs with cognitive or behavioral treatment and recovery support groups.  For some 




You need to work a program.  I need to work a program and that involves using a 
medication, Vivitrol, and going to counseling and meetings [recovery support 
groups].  Unless you’re working a program, it’s not going to work.  Going to 
counseling, you know, working on your head stuff is what you need.  Vivitrol 
isn’t going to change your head stuff, your thinking about getting high.   
Another participant candidly shared about his experience in psychosocial treatment, “We talk 
about relapse prevention and how to handle your emotions.  Without that, I’d be in jail, getting 
high, or dead.”  One participant even mentioned attending psychosocial treatment more often 
than required by drug court.  The participant said, “Although treatment wants you to do one a 
week, I take advantage of the support and go like four or so times a week.” Other participants 
stated, “I think it’s just obvious that you need treatment to go along with the medically assisted 
treatment” and combining MATs with psychosocial treatment results in, “improved mood, less 
cravings, just feeling better, and feeling more motivated.”   
Overall, the majority of participants felt that one of the most helpful aspects of drug court 
in treating their opioid use disorders was participating in psychosocial treatments.  Participants, 
whether or not they were on a MAT, provided examples on how the use of cognitive (e.g. 
cognitive restructuring) and behavioral therapies (e.g. relapse prevention) supported their 
recovery, and they felt that MATs should be used in combination with these types of treatment.  
The negative case analysis revealed that only 3 (8%) participants had experiences that conflicted 
with the theme.  All three comments, however, were related to difficulties with balancing the 
demands of psychosocial treatment with other responsibilities, as compared to viewing these 
additional treatments as unhelpful.  For example, a participant shared this lived experience: 
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They [psychosocial treatment] don’t understand a lot with all the stuff we have to 
do.  They [psychosocial treatment] set it up to make sure, you know what I mean, 
that we are busy.  With all the counseling we have to attend, it gets stressful and, 
ask everybody, it’s a hell of a lot of stress to stay sober.   
The uneasy relationship between harm reduction and drug court programming  
Twenty of the 38 participants (53%) shared thoughts, opinions, and lived experiences that 
contributed to the theme of an uneasy relationship between harm reduction and abstinence-based 
drug court programming, demonstrated through the quotes below.  Overall, the majority of 
participants had favorable views toward harm reduction.  In this case, harm reduction was 
conceptualized as reducing or abstaining from illicit opioid use, such as heroin, even if 
continuing to use other substances, and they viewed MATs as an important intervention in 
achieving this goal.  The problem, however, is that the drug court in this study is guided by an 
abstinence-based philosophy of treatment, consistent with the majority of U.S. drug courts.  
Therefore, participants who maintain abstinence from opioids but use other drugs can face 
sanctions from the drug court, which may include incarceration.  Throughout the focus groups, 
multiple participants shared their observations that other drug court participants have abstained 
from opioids in drug court but began to use other substances.  One participant, for instance, 
shared this observation:  
One of the other downfalls is the shift in the drug of abuse, or drug of use.  The 
switch from opiates over to methamphetamine.  Stuff like that.  That is one thing 
we’ve seen a lot more of, more positive drug tests with the medication-assisted 
treatment guys, especially positives for methamphetamine.   
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For some of the participants, methamphetamine was most commonly identified as the drug used 
to replace opioids.  It is unlikely that this phenomenon is due to a correlation between MATs and 
methamphetamine.  A more plausible explanation is that methamphetamine was more readily 
available in the community; therefore, this increased the likelihood of methamphetamine use for 
those who were abstaining from opioids but wanted to use another drug.  Regardless, there was a 
process of substituting opioids for other drugs for some participants.  One participant discussed 
the cognitive process that may explain why some individuals on MATs use non-opioids, such as 
marijuana or cocaine.  Specifically, the participant said:   
There is a perception because heroin is so devastating, so fast, that even highly 
addicted people with very advanced substance use disorders know that, oh my 
god, I got to get off this.  They take the med [medication-assisted treatment], 
they’re off heroin and start thinking, alright, now I can do these other things.  
Alcohol was never my problem, or weed should be legalized anyway, or what’s 
wrong with a little cocaine, it’s not heroin.    
The process of substituting one drug for another does not seem to be limited to stimulants, such 
as methamphetamine or cocaine, or marijuana.  Some participants shared their lived experiences 
with using a MAT outside of medical supervision to maintain their recovery from heroin.  In this 
instance, a participant shared the experiences of others using a non-prescribed MAT to prevent a 
relapse on heroin.  The participant shared: 
I have known people who were using heroin and they don’t want to relapse on 
heroin, so they’ll go find somebody who has Suboxone and they’ll use their 
Suboxone instead of relapsing on heroin.  They think that’s a better alternative 
than going back and using heroin.   
16 
 
The following participant shared that his drug of choice was heroin and, consistent with a 
harm reduction model of recovery, his goal was to maintain abstinence from his drug of 
choice.  Furthermore, the participant gave an example of how others also see it as 
progress and offer praise when an individual maintains abstinence from heroin despite 
also using other substances.  The participant stated:  
They still kind of look down upon it, of course, because, you know, it’s still you 
failed [positive drug test] for something, but they still do high-fives and 
congratulate you because you didn’t do your drug of choice.  You’re still clean 
this long from your drug of choice.  I’ve been 8 months clean off heroin.  So, for 
me, as long as I don’t use heroin, I am doing good.   
A participant provided a notable response to the previous quote, stating, “Maybe we are all 
inherently hardwired to believe in harm reduction.”   
The negative case analysis revealed that only 1 (3%) participant shared an experience that 
conflicted with the theme, and this conflicting statement was specific to the use of 
buprenorphine/naloxone and methadone.  The participant shared: 
I feel like Vivitrol would help because you can’t get high if you have that, but in 
my personal opinion, I don’t feel like you should take a medication 
[buprenorphine/naloxone or methadone] because it’s just going from one drug to 
another, like using it as a crutch. 
Discussion 
Overall, drug court participants in this study felt that medications such as Suboxone 
(buprenorphine/naloxone), Vivitrol (naltrexone), and methadone were helpful in many ways, 
such as reducing cravings, minimizing withdrawal symptoms, and improving functioning in 
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major areas of life, such as family relationships and employment.  This belief was shared by both 
drug court participants who were currently taking MATs to support their recovery and those who 
were not on MATs.     
As noted by participants in this study, a recommended approach to treating those who 
have opioid use disorders is to utilize MATs in combination with other psychosocial treatments.  
This theme was promising because it provided validation that using MATs in combination with 
psychosocial interventions is perceived by drug court participants as an effective approach for 
treating opioid use disorders, which aligns with the guidelines and recommendations of the 
American Society of Addiction Medicine for treating opioid use disorders (Kampman & Jarvis, 
2015).  Since drug courts have not often supported the use of MATs and have traditionally 
created barriers to the use of these treatments, it was promising that participants still perceived 
these treatments to be helpful despite messages they might receive otherwise.  For example, 
despite the evidence that MATs and counseling are effective interventions in treating opioid use 
disorders, many U.S. drug courts do not allow participants on opioid agonists and some judges or 
other stakeholders order participants to discontinue medications, even when they are 
recommended by a medical professional (Knopf, 2015).  The magnitude of this problem has 
warranted intervention from the U.S. federal government, and the Substance Abuse and Mental 
Health Services Administration (SAMHSA) recently released a statement emphasizing that 
SAMHSA-funded drug courts can no longer deny individuals admission into drug court because 
they are on an opioid agonist or mandate individuals to discontinue the use of MATs (Knopf, 
2015).  Despite these barriers, the participants from this study provide validation that MATs are 
viewed as helpful in combination with psychosocial therapies, such as cognitive restructuring, 
motivational interviewing, and relapse prevention.  Therefore, it is recommended that drug 
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courts allow participants to take MATs and also refer them to treatment providers who have 
expertise in cognitive and behavioral therapies.   
Participants’ responses also highlighted a discrepancy between drug court expectations 
and the harm reduction approach used by many participants, and the way both parties defined 
and conceptualized harm reduction.  For example, the drug court in this study acknowledges that 
the use of full (e.g. methadone) or partial (e.g. buprenorphine) opioid agonists to support 
recovery is consistent with a harm reduction model and permitted in the drug court when used 
under medical supervision.  Some of the drug court participants in this study, however, reported 
another form of harm reduction that is not permitted in the drug court.  After taking MATs, some 
participants reported that they discontinued opioid use but then began using other drugs.  This 
would be consistent with a harm reduction approach to the treatment of substance use disorders, 
as the risk of overdose and death is greatly diminished if an individual is no longer using opioids.   
U.S. drug courts will most likely not see this as an acceptable harm reduction approach to 
recovery, though, since most U.S. drug courts are guided by an abstinence-only philosophy of 
treatment.  Reducing drug use or switching from more harmful drugs (e.g. opioids) to less 
harmful drugs (e.g. marijuana) are typically not seen as progress in U.S. drug courts.  Continued 
drug use of any type could even result in progressive sanctions and ultimately termination from 
drug court.  Whether a drug court operates under an abstinence-based or harm reduction lens of 
treatment and recovery, it is important for drug courts to be aware of the behavior identified in 
this study and, consistent with the drug court model (NADCP, 2004), respond in a non-
adversarial, therapeutic manner.   
The abstinence-only philosophy is not universal, however, particularly with non-U.S. 
drug courts (Holst, 2010).  Irish drug treatment courts are one example (Loughran et al., 2015).  
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If a drug court participant enters the Irish program using opioids and eliminates their opioid use 
throughout treatment, yet continues to use alcohol and/or marijuana, this may be viewed as 
progress and could still lead to program completion.  In Ireland, the drug treatment court places 
tremendous value on assisting participants to develop skills for employment and enhancing their 
education.  This is promising because employment and having at least a high school diploma or 
equivalent are consistently strong predictors of drug court completion and non-recidivism 
(Gallagher, 2013; Gill, 2016; Shaffer et al., 2011b).  Drug court programming and polices vary 
from one country to the next, presumably to meet the individualized needs of the participants 
they serve.   
Limitations 
This study has several limitations.  First, the findings of this study cannot be generalized 
beyond the research sample.  The findings are limited to the 38 drug court participants who 
chose to participate in a focus group, and the themes drawn from the data are only applicable to 
the one drug court in this study.  With that stated, however, it is plausible that the themes from 
this study, such as drug court participants practicing harm reduction, are applicable to other drug 
courts and the discussion may help guide drug court programming and future research.  It is 
recommended that all drug courts incorporate qualitative methodologies into their program 
evaluations to assess their participants’ experiences in drug court.  Additionally, program 
evaluation is a key component of the drug court model (NADCP, 2004), and incorporating 
qualitative methodologies into program evaluations will capture data that quantitative 
methodologies simply cannot, such as the benefits of and barriers to using MATs in drug court.  
Overall, MATs are an established and effective intervention for treating opioid use 
disorders.  However, MATs have limitations and barriers to service delivery, particularly in the 
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criminal justice system.  The experiences and opinions of drug court stakeholders, who play a 
key role in the service delivery of MATs in drug court, are not captured in this study.  As a 
result, it is recommended that future research collect data on drug court stakeholders’ views on 
the use of MATs in the program.  It is suspected that stakeholders, such as the judge, court 
coordinator, treatment providers, prosecutor, and defense attorneys, will offer a unique insight 
into the role of drug courts in treating opioid use disorders.  Last, as common in qualitative 
research, the findings may have been impacted by social desirability bias.  This is particularly 
true in this study, as data were collected through focus groups and research participants may 
have been selective in what they shared because other drug court participants were present.  
Focus groups have many strengths, such as offering synergistic and comprehensive answers to 
questions, but can also be impacted more heavily by social desirability bias.  To potentially 
minimize this limitation, future research should consider collecting data through individual 
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